Abstract
Background: Management of dual antiplatelet therapy (DAPT) in the perioperative setting is challenging, particularly in complex patient populations, such as those with underlying coagulopathy and/or recent percutaneous coronary interventions. Methods: In this case series, we describe the perioperative use of cangrelor bridge therapy in two patients undergoing liver transplantation after recent coronary drug-eluting stent placement. Outcomes: In both patient cases, cangrelor use as a P2Y12 bridge at a dose of 0.75 μg/kg/min was safe and effective. Both patients were successfully switched back to their oral DAPT regimen post-operatively without additive bleeding or thrombotic complications. Conclusion: The use of cangrelor as bridge therapy in high-risk perioperative liver transplant patients appears to be a viable option when DAPT is warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 263-267 |
Number of pages | 5 |
Journal | Pharmacotherapy |
Volume | 42 |
Issue number | 3 |
Early online date | Jan 25 2022 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- cangrelor
- dual antiplatelet therapy (DAPT)
- liver transplant
- perioperative
- Adenosine Monophosphate/analogs & derivatives
- Percutaneous Coronary Intervention/adverse effects
- Drug-Eluting Stents
- Liver Transplantation
- Humans
- Platelet Aggregation Inhibitors
- Treatment Outcome
- Drug Therapy, Combination
ASJC Scopus subject areas
- Pharmacology (medical)